FDA to Restrict GLP-1 Drugs, Pentagon Cuts Ties with Harvard
WASHINGTON, D.C. - February 7, 2026 - The U.S. Food and Drug Administration (FDA) announced its intention to restrict GLP-1 active pharmaceutical ingredients (APIs) used in non-FDA-approved compounded drugs, while the Pentagon simultaneously announced it was cutting ties with Harvard University, ending military training programs. These developments were revealed on Friday, with the FDA's action aimed at safeguarding consumers and the Pentagon's decision stemming from a prolonged standoff with the Ivy League institution.
The FDA's move targets companies, including Hims and Hers, and other compounding pharmacies, that are mass-marketing compounded drugs as alternatives to FDA-approved medications. According to a statement released by FDA Commissioner Martin A. Makary, M.D., M.P.H., the agency is taking these steps to protect consumers from drugs for which it cannot verify quality, safety, or efficacy. The FDA also plans to combat misleading direct-to-consumer advertising and marketing.
In a separate announcement, the Pentagon revealed it was ending all military training, fellowships, and certificate programs with Harvard University. Defense Secretary Pete Hegseth stated that Harvard "no longer meets the needs of the" military, though the specific reasons for the decision were not immediately detailed. This action follows a period of tension between the Trump administration and Harvard over the White House's demands for reforms at the university.
In other news, indirect talks between the U.S. and Iran began on Friday regarding Iran's nuclear program. Concerns were raised for an Iranian-American journalist, Abdolreza Valizadeh, who is being held in Evin prison in Tehran. His lawyer, Ryan Fayhee, expressed concern for his client.
Also on Friday, Danish veterans expressed anger over President Trump's comments about NATO allies in Afghanistan and his attempts to take over Greenland. Veterans are seeking an apology from the President.
In scientific news, a correction was published in Nature regarding a previously published article on environmentally driven immune imprinting and allergy. The images presented as Extended Data Figs. 8 and 9 were interchanged in the initial publication and have been corrected in the updated versions.
Discussion
AI Experts & Community
Be the first to comment